TransCode Therapeutics Open Letter to Shareholders
12. November 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Open Letter to Shareholders
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
05. November 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
23. Oktober 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
10. Oktober 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17. September 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
10. September 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05. September 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15. August 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
TransCode Therapeutics, Inc. Announces Closing of Public Offering
24. Juli 2024 16:05 ET
|
TransCode Therapeutics, Inc.
Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
22. Juli 2024 22:30 ET
|
TransCode Therapeutics, Inc.
Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t